The Cleveland Clinic issued a statement on Wednesday saying its panel of experts decided against carrying the drug Aduhelm, also called aducanumab, after having "reviewed all available scientific evidence."
"Based on the current data regarding its safety and efficacy, we have decided not to carry Aducanumab at this time. However, we support continued research in this area, and when additional data become available, we will re-evaluate this medication for use in our patients."A spokesperson for the Cleveland Clinic clarified to The Hill that individual physicians will be allowed to prescribe Aduhelm. But patients would need to have the drug administered intravenously monthly from a different health provider.















Comment: The controversy surrounding the authorization and usage of this drug should be cut and dry. It is either a viable, safe and beneficial choice...or it isn't. This is another case of serving profit over health in collusion with the FDA.